March 27, 2017 / 11:39 AM / in 4 months

BRIEF-Allergan and Paratek announce positive results from two phase 3 trials of sarecycline

1 Min Read

March 27 (Reuters) - Allergan Plc:

* Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne

* Allergan Plc - plans to file a new drug application (NDA) to U.S. Food & drug administration (fda) in second half of this year

* On track for FDA submission in second half of 2017

* Sarecycline was statistically significantly superior to placebo with respect to primary efficacy endpoints Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below